Medicare GLP-1 Bridge, Explained: Who Qualifies and How the $50-a-Month Program Works

The Medicare GLP-1 Bridge is a temporary federal demonstration, running July 1, 2026 through December 31, 2027, that lets eligible Medicare Part D beneficiaries get certain GLP-1 medications for weight management — Wegovy, Zepbound (KwikPen), and Foundayo — for a flat $50-a-month copay. You don't apply yourself: your prescriber submits a prior authorization attesting that you meet the program's published eligibility rules, which are based on your BMI when you started (or start) GLP-1 therapy plus, at lower BMI levels, specific qualifying conditions. You can check whether you might qualify at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE.

The short version

• The Bridge runs July 1, 2026 – December 31, 2027. It's a demonstration, not a permanent change to Medicare drug coverage.

• Eligible beneficiaries pay a $50 copay per monthly supply for Foundayo, Wegovy (injection and tablets), or Zepbound (KwikPen only) prescribed for weight management alongside ongoing lifestyle changes.

• The published eligibility tiers: BMI ≥ 35; or BMI ≥ 30 plus heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease (stage 3a+); or BMI ≥ 27 plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease — measured at the time GLP-1 therapy was initiated, even if that was years ago.

• Key exclusions: people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH aren't eligible for the Bridge — those diagnoses can qualify for GLP-1 coverage through the regular Part D plan instead.

• The fine print matters: the $50 copay doesn't count toward your deductible or out-of-pocket (TrOOP) totals, and no Extra Help/low-income subsidy applies.

• Questions go to 1-800-MEDICARE, not your drug plan — the Bridge runs outside the normal Part D system.

• This is general education, not medical or coverage advice. Whether a GLP-1 is right for you is a decision for you and your clinician.

What is the Medicare GLP-1 Bridge?

For years, Medicare Part D was generally prohibited from covering drugs prescribed solely for weight loss. GLP-1 medications were covered only when prescribed for specific other indications — type 2 diabetes, cardiovascular risk reduction, and more recently sleep apnea and MASH. If you wanted a GLP-1 purely to reduce excess weight, Medicare typically wouldn't pay, and list prices run over $1,000 a month.

The Medicare GLP-1 Bridge changes that, temporarily. It's a short-term demonstration run by the Centers for Medicare & Medicaid Services (CMS) under its statutory demonstration authority, designed to test expanded access to GLP-1s for weight management while CMS gathers utilization data ahead of a potential broader model (called BALANCE) in Part D.

A few structural points worth understanding, because they explain most of the program's quirks:

The Bridge operates outside the normal Part D benefit. Your drug plan doesn't process these claims — a single central processor handles prior authorization, claims, and pharmacy payment on CMS's behalf. That's why your plan can't answer Bridge questions, why the copay doesn't touch your deductible, and why questions go to 1-800-MEDICARE instead.

Participating manufacturers agreed to supply the eligible drugs at a negotiated net price of $245 per monthly supply — a fraction of typical list prices. Eligible beneficiaries pay $50 of that; the program covers the rest.

And it's temporary by design: the demonstration ends December 31, 2027. Anyone starting a GLP-1 through the Bridge should plan with their clinician for what happens after (more on that below).

Which drugs does the Bridge cover?

Three products qualify, and only when prescribed to reduce excess body weight and maintain weight reduction:

Two common points of confusion. First, Ozempic is not on the list — it's the same active ingredient as Wegovy but approved for type 2 diabetes, which is covered through regular Part D, not the Bridge. Second, the Zepbound restriction is real: if you currently use Zepbound vials, only the KwikPen version is available at the $50 copay. Pen needles for the KwikPen are not covered and are purchased separately.

CMS notes the drug list may be updated during the demonstration, so it's worth re-checking the CMS program page if your medication isn't listed today.

Who qualifies: the program's published eligibility rules

Eligibility has three layers: your Medicare plan type, the clinical criteria, and the exclusions. To be clear at the outset — these are the program's published rules, not a determination about you. Only your prescriber can attest to the clinical criteria, and only a clinician can tell you whether a GLP-1 makes sense for your health.

1. You need the right kind of Medicare drug coverage

You must be enrolled in a standalone Part D prescription drug plan (PDP) or a Medicare Advantage coordinated care plan with drug coverage (HMO, HMO-POS, or local/regional PPO MA-PD plans). Beneficiaries in Special Needs Plans, employer/union group waiver plans, and the LI NET program are also eligible. People enrolled only in private fee-for-service plans, cost plans, or PACE are not, unless they also have a standalone PDP. Dually eligible (Medicare + Medicaid) beneficiaries in eligible plan types can participate.

2. You must meet one of three clinical tiers

Your prescriber must attest that the GLP-1 is being prescribed to reduce excess body weight and maintain weight reduction, in combination with ongoing lifestyle modification (structured nutrition and physical activity), and that you're 18 or older and met one of these at the time you started GLP-1 therapy:

• BMI ≥ 35 — no additional condition required

• BMI ≥ 30 plus at least one of: heart failure with preserved ejection fraction; uncontrolled hypertension (blood pressure above 140/90 despite two blood-pressure medications); or chronic kidney disease, stage 3a or above

• BMI ≥ 27 plus at least one of: prediabetes (per American Diabetes Association criteria); a previous heart attack; a previous stroke; or symptomatic peripheral artery disease

Note the timing detail, because it helps more people than it hurts: the criteria apply at initiation of therapy, even if that was before July 2026 or before you joined Medicare. CMS's own example: someone who started a GLP-1 in September 2024 with a BMI of 37, whose BMI is now 34 thanks to the medication, still qualifies under the BMI ≥ 35 tier.

3. The exclusions — and why they exist

You are not eligible for the Bridge if you have a diagnosis of type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis). This surprises people, but the logic is routing, not denial: those diagnoses already qualify for GLP-1 coverage through your regular Part D plan, so CMS directs those prescriptions to the existing benefit. Similarly, if you're already receiving a GLP-1 through your Part D plan for a covered indication, you stay with your plan's coverage.

One nuance for people with cardiovascular history: having had a heart attack or stroke can qualify you (in the BMI ≥ 27 tier), but if your clinician is prescribing the GLP-1 specifically to reduce cardiovascular event risk rather than for weight management, that prescription belongs with your Part D plan instead. Your prescriber makes that call.

What it actually costs — and the fine print

The headline is simple: $50 per monthly supply, with no Part D deductible applied. Behind that, CMS negotiated a $245-per-month net price with manufacturers, and the program covers the gap.

The fine print is where budgeting mistakes happen:

• The $50 doesn't count toward your true out-of-pocket (TrOOP) costs. Bridge spending won't help you reach the annual Part D out-of-pocket cap, because it happens outside the Part D benefit.

• There is no low-income subsidy. If you get Extra Help with drug costs, it does not apply here — the copay is $50 for everyone.

• Pen needles (for Zepbound KwikPen) are a separate out-of-pocket purchase.

That's still a dramatic discount from cash prices, but if you're on a tight fixed income, $50 a month for up to 18 months is a real commitment worth discussing — including with your State Health Insurance Assistance Program (SHIP), which offers free Medicare counseling.

How to check your eligibility and get started

There's no beneficiary application form. The path runs through your prescriber:

1. Check the program's rules against your situation at Medicare.gov/glp1bridge, or call 1-800-MEDICARE (1-800-633-4227; TTY 1-877-486-2048). Don't call your drug plan — the Bridge runs outside it, and plans can't look up Bridge information.

2. Talk with a clinician about whether a GLP-1 is appropriate for you at all — the medical question comes before the coverage question. That conversation should cover your full health picture, other medications, side effects, and what happens when the demonstration ends.

3. Your prescriber submits the prior authorization (electronically or by fax) attesting that you meet the clinical criteria. This is a provider attestation, not paperwork you file yourself.

4. Fill the prescription at a pharmacy, where the claim is processed through the program's central processor at the $50 copay.

Which clinician should you talk to?

Primary care physicians handle most GLP-1 prescriptions and are the natural starting point — and any prescriber managing your weight-related care can submit the Bridge prior authorization. Depending on your situation, an endocrinologist or an obesity-medicine specialist may be a better fit, especially if you have overlapping metabolic conditions like prediabetes or kidney disease. If you're not sure which type of doctor you need, start with primary care and ask about referral. And because the Bridge doesn't change how your visits are covered, it still pays to confirm any new clinician is in-network for your plan before you book.

Good questions to bring: Am I a reasonable candidate for a GLP-1 given my full health history? Do I meet the Bridge's published criteria, and were they met when I first started therapy? What's our plan for lifestyle support alongside the medication? And what's our plan for December 2027, when the demonstration ends?

Plan for the end date

The Bridge expires December 31, 2027, unless CMS extends or replaces it. That matters clinically, not just financially: stopping a GLP-1 commonly leads to regaining some weight, so a medication you can only afford during the demonstration deserves an exit plan from day one. Options your clinician might discuss include transitioning to coverage under a qualifying diagnosis if one develops, other affordability programs, or a structured plan for tapering with intensified lifestyle support. None of that is a reason to avoid the program — it's a reason to start it with a plan.

If you have both Medicare and access to an employer or retiree plan (yours or a spouse's), the coverage picture is different again — our guide to how employers are covering GLP-1s in 2026 covers that side.

FAQs

Do I need to apply for the Medicare GLP-1 Bridge?

No. There's no beneficiary application. Your prescriber submits a prior authorization request attesting that you meet the program's clinical criteria. Your role is to confirm your plan type is eligible and have the conversation with your clinician. Questions go to 1-800-MEDICARE or Medicare.gov/glp1bridge.

Does the $50 copay count toward my Part D deductible or out-of-pocket maximum?

No. The Bridge operates outside the Part D benefit, so the Part D deductible doesn't apply to Bridge prescriptions, and the $50 copay does not count toward your true out-of-pocket (TrOOP) total for the year.

I have type 2 diabetes. Can I use the Bridge?

No — but you likely don't need it. Type 2 diabetes is an indication your Part D plan can already cover GLP-1s for (such as Ozempic or Mounjaro). The Bridge is specifically for people seeking a GLP-1 for weight management who don't have a Part D-covered indication. The same routing applies to moderate-to-severe obstructive sleep apnea and noncirrhotic MASH.

Is Ozempic covered by the GLP-1 Bridge?

No. The eligible drugs are Foundayo, Wegovy (injection and tablets), and Zepbound (KwikPen formulation only). Ozempic is approved for type 2 diabetes and is handled through regular Part D coverage when prescribed for a covered indication.

I'm on a Medicare Advantage plan. Am I eligible?

If your plan is a coordinated care plan with drug coverage (HMO, HMO-POS, or local/regional PPO MA-PD), yes — those plan types are eligible, along with standalone Part D plans, Special Needs Plans, and employer/union group waiver plans. Private fee-for-service plans, cost plans, and PACE are not eligible unless you also have a standalone PDP.

I started a GLP-1 two years ago and my BMI has come down. Do I still qualify?

Possibly — the clinical criteria are assessed at the time you initiated GLP-1 therapy, not today. CMS gives exactly this example: a person who started therapy at BMI 37 and is now at 34 still meets the BMI ≥ 35 tier. Your prescriber attests to what was true when you started.

What happens when the program ends in December 2027?

The demonstration is currently scheduled to end December 31, 2027. CMS has signaled the Bridge is partly a data-gathering step ahead of a potential broader Part D model, but nothing is guaranteed. Build an after-the-Bridge plan with your clinician from the start.

Does Extra Help lower the $50 copay?

No. The low-income subsidy (Extra Help) does not apply to Bridge prescriptions. The copay is $50 per monthly supply for all eligible beneficiaries. If cost is a barrier, your local SHIP counselor can help you think through options.

Key takeaways

• The Medicare GLP-1 Bridge makes Wegovy, Zepbound (KwikPen), and Foundayo available for a $50 monthly copay to eligible Part D beneficiaries — for weight management, from July 1, 2026 through December 31, 2027.

• Eligibility is tiered by BMI at the time GLP-1 therapy started (≥35 alone; ≥30 or ≥27 with specific qualifying conditions), attested by your prescriber via prior authorization — you don't apply yourself.

• Type 2 diabetes, moderate-to-severe sleep apnea, and noncirrhotic MASH route to regular Part D coverage instead of the Bridge.

• The $50 doesn't count toward your deductible or out-of-pocket cap, and Extra Help doesn't apply.

• The program is temporary — start it with an end-of-2027 plan, built with your clinician.

• Verify everything against the primary sources: Medicare.gov/glp1bridge and 1-800-MEDICARE.

Find the right clinician to talk it through

The Bridge's coverage rules are only half the question — whether a GLP-1 fits your health is the other half, and that takes a clinician who knows your full picture. Sidewalk helps you understand your health and find the right provider for that conversation, whether that's a primary care physician, an endocrinologist, or an obesity-medicine specialist near you. Take the free assessment or find a provider at joinsidewalk.com.

This article is for educational purposes only and is not medical, insurance, or coverage advice. It does not diagnose or treat any condition, does not determine your individual eligibility for any program, and is not a substitute for care from a qualified professional. Program rules may change; verify current details with Medicare.gov or 1-800-MEDICARE, and talk with your clinician about your situation.

References

1. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge — program page and FAQs. Page last modified July 13, 2026.

2. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge — Information for Providers (clinical criteria, eligible drugs, plan-type eligibility, prior authorization process).

3. Medicare.gov. Fact sheet: Medicare GLP-1 Bridge — GLP-1 Drugs for $50 a Month (PDF).

4. Centers for Medicare & Medicaid Services. Press release: CMS Launches Medicare GLP-1 Bridge ($245 negotiated net price; central processor).

5. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge — Information for Prescribers (PDF).

6. Medicare Rights Center. GLP-1 Weight-Loss Drug Demonstration Begins July 2026 (June 4, 2026).

7. KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge.

Medical review: pending — this draft awaits review by a credentialed clinical reviewer before publication.